A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients

NCT03299829 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2020-08-18

No results posted yet for this study

Summary

This is a retrospective study to assess the clinical efficacy and safety of trientine in Wilson's disease patients

Conditions

  • Trientine Treatment for Wilson's Disease

Interventions

DRUG

Trientine

Trientine is a chelating agent for removing the copper from the body

Sponsors & Collaborators

  • Excelsior

    lead INDUSTRY

Principal Investigators

  • Chinchang Huange, Doctor · Chang Gung Memorial Hospital

Eligibility

Min Age
3 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-10
Primary Completion
2019-06-30
Completion
2019-12-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03299829 on ClinicalTrials.gov